Group to Introduce Certification of EHR Products

BY MARY ELLEN SCHNEIDER Senior Writer

BOSTON — A coalition of private sector informatics groups plans to launch a process for certifying electronic health record products late this year.

Certification will bring some predictability into the market for physicians, vendors, and payers, Mark Leavitt, M.D., who is chair of the Certification Commission for Healthcare Information Technology, said at a congress sponsored by the American Medical Informatics Association.

The commission's initial scope is to certify electronic health record (EHR) products for physician offices and other am-

	bul
The commission,	settin
which was	plan
	beta
founded last year,	produ
will be setting a	of a
-	ject in
baseline	ber.
standard, leaving	By
	the y
space for	comn
competition and	slated
-	lish
innovation above	tion
the standard.	ment
	outlir
usedue on four roundous four	

bulatory ngs. They to begin testing ucts as part pilot pron Septemthe end of vear, the mission is d to pubcertificarequires and to ne а

roadmap for vendors for requirements for the next 1-2 years, Dr. Leavitt said.

The roadmap is a key part of the commission's work because the cycle for getting new features, interfaces, and interoperability functions into a product can be 6-18 months or more. "We need to signal to the industry as to where we are going next, so it has time to respond," he said.

The certification commission was founded last year by the American Health Information Management Association, the Healthcare Information and Management Systems Society (HIMSS), and the National Alliance for Health Information Technology.

The three groups have provided seed funding and have loaned staff members to the effort. As the process moves forward, the commission will charge fees to the vendors to cover the cost of testing the products. They also plan to seek sustaining grants from other organizations to maintain their operations, said Dr. Leavitt, who is also the medical director at HIMSS.

Under the voluntary certification process, products will either be certified or not certified. "We are not trying to create a competitive rating system," Dr. Leavitt said.

The idea is that the commission will be setting a baseline standard, leaving space for competition and innovation above that standard. And the standard needs to be based on reality, he said, to get participation from vendors.

In the first year of certification, the members of the commission want to be sure that they don't create any requirements that will shut down the marketplace.

Dr. Leavitt, however, said he expects that, as the standards become more rigorous in the years to come, the marketplace will evolve to follow the certification process.

Currently, adoption is progressing slowly because the market lacks order and predictability.

For example, physicians won't buy electronic records systems until costs are lower, their own risk is lower, and the incentives are higher. However, it's hard for vendors to bring down prices when the sales volumes are so low and the sales cycle is so costly.

Payers have expressed interest in offering incentives for the use of EHRs, but many are concerned that if they start to offer incentives, an industry of minimal systems will spring up to capture that money, Dr. Leavitt said.

Certification is a way to take some of the risk out of the process for all the players, Dr. Leavitt said.

Another challenge is to make sure that there isn't a wave of adoption of products that aren't interoperable.

We want to ensure that these products that get adopted will be interoperable in this emerging infrastructure," Dr. Leavitt stated at the meeting. "The challenge is the infrastructure isn't there yet, it's emerging.


For more information on the certification timeline, visit www.cchit.org.

Topicort[®] (Desoximetasone)

(decommendative) organi 0.03 %, lopicorre (desommendative) organi 0.25 %, lopicorre (desommendative) and Topicorre (desommendative) organi 0.25% contain the active synthetic corticosteroid desoximetation (and Topicorre) (desoximetative) organi 0.25% contain the active synthetic corticosteroid desoximetative) organi 0.25% contain the active synthetic corticosteroid desoximetative) organi 0.25% contain the active synthetic corticosteroid desoximetative) organi 0.25% contain the active synthetic control control organized as anti-inflammatory and organized as anti-inflammatory as anti-inflammatory as anti-inflammatory as anti-inflammatory agents. of TOPICOCRT LP Cream 0.05% contains 0.5 mg of desoximetasone in an emollient cream base consisting strolatum, purified water, isopropyl myristate, lanolin alcohols, mineral oil, cetostearyl alcohol, and edetate

of TOPICORT Cream 0.25% contains 2.5 mg of desoximetasone in an emollient cream base consisting of white purified water, isopropyl myristate, landin alcohols, mineral oil, and cetostearyl alcohol. If OPICORT Gell 0.05% contains 0.5 mg of desoximatesore in a gal base consisting of purified water, docusate tate disodum, isopropyl myristate, carborner 940, troiamine, and SDAC-18 95%, alcohol. of TOPICORT Tourisment 0.25% contains 2.5 mg of desoximatesore in an ointment base consisting of white one is Pregna-1, 4-diene-3, 20-dione, 9-fluoro-11, 21-dihydroxy-16 -. has the molecular formula C₂₂H₂₉FO₄ and a molecular weight of 376.47. The CAS Registry Numbe

The structural formula is



ier, and the use of occlusive dressings. absorbed from normal intact skin. Inflammation and/or other disease processes absorption. Occlusive dressings substantially increase the percutaneous absorpt , occlusive dressings may be a valuable therapeutic adjunct for treatment of res

I through the skin, topical corticosteroids are handled through pha administered corticosteroids. Corticosteroids are bound to plasma administered corticostervicials. Corticostervicials are bound to plasma proteins in in are metabolized primarily in the liver and are then excreted by the kindenys. Some of the studies in men with Topicorff (denomination of the studies) in emerity of the studies in the with Topicorff (denomination of the studies). Some of the studies in the with Topicorff (denomination of the studies) and not detectable level in the block with tagged desoxim to the studies in the with the studies of the studies in the studies urine (4.1% + 2.3%) and feces (1.1% + 0.6%) and no detectable level (limit of sensitiv-ent i was applied topically on the back followed by occlusion for 24 hours. Seven days acativity was detected in urine or feces. The half-life of the material was 15 + 2 hours feces) between the third and fifth trial day. with Topicort[®] (desoutinetasone) Ontiment 0.25% with lagged desoutinetasone showed topically on the back followed by occlusion for 24 hours. The extent of absorption for a chacks. Structure with ontime the structure of the trial of the back followed by occlusion for 24 hours. The extent of absorption for an chacks. Structure with other similar structure darks have hours have not been applied by the structure of the back followed by occlusion for 24 hours. The extent of absorption for an chacks. Structure with other similar structured structure have hours have not hour redwinning.

NS s are contraindicated in those patients with a history of hype

am 0.05%; Topicort[®] (desoximetasone) Cream 0.25%; etasone) Ointment 0.25% are not for ophthalmic use.

In of topical corticosteroids has produced reversible hypothalamic-pituitary-adrenal (HPA) axis sup-ations of cushing's syndrome, hyperglycernia, and glucosuria in some patients. augment systemic absorption include the application of the more potent steroids, use over large onged use, and the addition of occlusive dressings. receiving a large does of a potent topical steroid applied to a large surface area or under an occlusive e evaluated periodically for evidence of HPA axis suppression by using the urinary tree corticol and less. If HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce optication, or to substitute a less potent steroid. site function is generally prompt and complete upon discontinuation of the drug. Infrequently, signs steroid withdrawal may occur, requiring supplemental systemic corticosteroids. Invariant integration of the second se erapy insulued. ical infections, the use of an appropriate antifungal or antibacterial agent should be se does not occur promptly, the corticosteroid should be discontinued until the infection

topical corticosteroids should receive the following information and instructions: cation is to be used as directed by the physician. It is for external use only. Avoid contact with should be advised not to use this medication for any disorder other than for which it was

I skin area should not be bandaged or otherwise covered or wrapped as to be occlusive unless

ysician. port any signs of local adverse reactions, especially under occlusive dressings. tric patients should be advised not to use tight-fitting diapers or plastic pants on a child e diaper area, as these garments may constitute occlusive dressings.



y be helpful in evaluating the hypothalamic-pituitary-adrenal (HPA) axis su

Mothers yow whether topical administration of corticosteroids could result in sufficient quantities in breast milk. Systemically administered corticosteroids are secre o have a deleterious effect on the infant. Nevertheless, caution should be ex ministered to a nursing woman.

on, Cushing's syndrome, and intracranial hypertens ticosteroids. Manifestations of adrenal suppression in

The following local adve	rse reactions are reported infrequently with topical c	orticosteroids, but may occur more frequent-
ly with the use of occlus	ive dressings. These reactions are listed in an app	roximate decreasing order of occurrence:
Burning	Hypertrichosis	Maceration of the skin
Itching	Acneiform eruptions	Secondary infection
Irritation	Hypopigmentation	Skin atrophy
Dryness	Perioral dermatitis	Striae
Folliculitis	Allergic contact dermatitis	Miliaria

AGE AND A

Cream 0.05%, Topicort[®] (desoximetasone) Crean oximetasone) Ointment 0.25% to the affected skir Rub in gently

HOW SUPPLIED

ne) Cream 0.05% is supplied in 5 gram tubes for physician sa ximetasone) Cream 0.25% is supplied in 5 gram tubes for physician samples. 15 gram and ximetasone) Gel 0.05% is supplied in 5 gram tubes for physician samples, 15 gram and netasone) Ointment 0.25% is supplied in 5 gram tubes for physician samples, 15 gram and es. trolled room temperature 15' - 30'C (59' - 86'F).

ceuticals Inc., Brampton, Ontario, Canada L6T 1C1 a division of Taro Pharmaceuticals U.S.A., Inc., Hawthorne, NY 10532 rod trademark of Taro Pharmaceuticals North America. Inc.



106-0505-